Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
hal.structure.identifierAcides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
dc.contributor.authorCUNHA, Anthony
ORCID: 0000-0003-0946-4701
IDREF: 25971206X
hal.structure.identifierAcides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
dc.contributor.authorGAUBERT, Alexandra
IDREF: 150487983
hal.structure.identifierAcides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
dc.contributor.authorLATXAGUE, Laurent
ORCID: 0000-0002-6115-7437
IDREF: 074748114
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorDEHAY, Benjamin
dc.date.accessioned2022-10-10T10:39:37Z
dc.date.available2022-10-10T10:39:37Z
dc.date.issued2021-07-08
dc.identifier.issn1999-4923en_US
dc.identifier.urioai:crossref.org:10.3390/pharmaceutics13071042
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/148371
dc.description.abstractEnTreatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis).
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.sourcecrossref
dc.subject.enPLGA nanoparticles
dc.subject.enNeurodegenerative diseases
dc.subject.enDrug delivery
dc.subject.enCentral nervous system
dc.subject.enNeuroprotective drugs
dc.title.enPLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/pharmaceutics13071042en_US
dc.subject.halSciences du Vivant [q-bio]en_US
dc.identifier.pubmed34371733en_US
bordeaux.journalPharmaceuticsen_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesInstitut des Maladies Neurodégénératives (IMN) - UMR 5293en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.institutionINSERM
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcedissemin
hal.identifierinserm-03285083
hal.version1
hal.exportfalse
workflow.import.sourcedissemin
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2021-07-08&rft.volume=13&rft.issue=7&rft.eissn=1999-4923&rft.issn=1999-4923&rft.au=CUNHA,%20Anthony&GAUBERT,%20Alexandra&LATXAGUE,%20Laurent&DEHAY,%20Benjamin&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record